Appropriateness of Prescribing Dabigatran Etexilate and Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation: A Prospective Study

Annals of Pharmacotherapy

Volumn 48, Issue 10, 2014, Pages 1258-1268

  Larock, Anne Sophie ^a,b   Mullier, François ^a,b   Sennesael, Anne Laure ^a,b   Douxfils, Jonathan ^b   Devalet, Bérangère ^a,b   Chatelain, Christian ^a,b   Dogné, Jean Michel ^b   Spinewine, Anne ^a,b,c  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

dabigatran etexilate; drug related side effects and adverse reactions; medication errors; rivaroxaban; atrial fibrillation

Indexed keywords

DABIGATRAN ETEXILATE; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INAPPROPRIATE PRESCRIBING; MAJOR CLINICAL STUDY; MALE; MEDICATION APPROPRIATENESS INDEX; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONVALVULAR ATRIAL FIBRILLATION; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; FEMALE; HEMORRHAGE; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; PYRIDINES; THIOPHENES;

EID: 84907379537     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014540868     Document Type: Article

References (30)

1. Mantha S,Cabral K,Ansell J.New avenues for anticoagulation in atrial fibrillation.Clin Pharmacol Ther. 2013;93:68-77.
2. Huisman MV,Lip GY,Diener HC,Brueckmann M,van Ryn J,Clemens A.Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.Thromb Haemost. 2012;107:838-847.
3. Ten Cate H.New oral anticoagulants: discussion on monitoring and adherence should start now!.Thromb J. 2013;11:.
4. Ten Cate H.Monitoring new oral anticoagulants, managing thrombosis, or both?.Thromb Haemost. 2012;107:803-805.
5. Baglin T,Keeling D,Kitchen S.Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.Br J Haematol. 2012;159:427-429.
6. Pernod G,Albaladejo P,Godier A, et al.Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP): March 2013.Arch Cardiovasc Dis. 2013;106 (6-7): 382-393.
7. Rodriguez RA,Carrier M,Wells PS.Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?.J Thromb Haemost. 2013;11:390-394.
8. Schulman S,Shortt B,Robinson M,Eikelboom JW.Adherence to anticoagulant treatment with dabigatran in a real-world setting.J Thromb Haemost. 2013;11:1295-1299.
9. Hussain S,Gebran N,Hussain K,Soliman K.Drug use evaluation of dabigatran in a tertiary care hospital in United Arab Emirates.Eur J Hosp Pharm. 2013;20:106-109.
10. Carley B,Griesbach S,Larson T,Krueger K.Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting.Am J Cardiol. 2014;113:650-654.
11. Sorensen R,Gislason G,Torp-Pedersen C, et al.Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.BMJ Open. 2013;3 (5): pii-e002758.
12. Lim SL,Maxwell E.An audit of dabigatran etexilate prescribing in Victoria.Med J Aust. 2013;198:314-315.
13. Douxfils J,Mullier F,Loosen C,Chatelain C,Chatelain B,Dogne JM.Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.Thromb Res. 2012;130:956-966.
14. Douxfils J,Mullier F,Robert S,Chatelain C,Chatelain B,Dogne JM.Impact of dabigatran on a large panel of routine or specific coagulation assays: laboratory recommendations for monitoring of dabigatran etexilate.Thromb Haemost. 2012;107:985-997.
15. Hanlon JT,Schmader KE,Samsa GP, et al.A method for assessing drug therapy appropriateness.J Clin Epidemiol. 1992;45:1045-1051.
16. Spinewine A,Schmader KE,Barber N, et al.Appropriate prescribing in elderly people: how well can it be measured and optimised?.Lancet. 2007;370:173-184.
17. Spinewine A,Swine C,Dhillon S, et al.Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial.J Am Geriatr Soc. 2007;55:658-665.
18. Spinewine A,Dumont C,Mallet L,Swine C.Medication appropriateness index: reliability and recommendations for future use.J Am Geriatr Soc. 2006;54:720-722.
19. Wouters H,Thijs V,Annemans L.Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.J Med Econ. 2013;16:407-414.
20. Coyle D,Coyle K,Cameron C, et al.Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.Value Health. 2013;16:498-506.
21. Kirley K,Qato DM,Kornfield R,Stafford RS,Alexander GC.National trends in oral anticoagulant use in the United States, 2007 to 2011.Circ Cardiovasc Qual Outcomes. 2012;5:615-621.
22. Breuer L,Ringwald J,Schwab S,Kohrmann M.Ischemic stroke in an obese patient receiving dabigatran.N Engl J Med. 2013;368:2440-2442.
23. Pfeilschifter W,Luger S,Brunkhorst R,Lindhoff-Last E,Foerch C.The gap between trial data and clinical practice: an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.Cerebrovasc Dis. 2013;36:115-119.
24. Harper P,Young L,Merriman E.Bleeding risk with dabigatran in the frail elderly.N Engl J Med. 2012;366:864-866.
25. Hellwig T,Gulseth M.Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?.Ann Pharmacother. 2013;47:1478-1487.
26. European Medicines Agency. Assessment Report Xarelto. Procedure N° EMEA/H/C/000944/II/0023. June2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report__Variation/human/000944/WC500151973.pdf.
27. Dager WE,Gulseth MP.Implementing anticoagulation management by pharmacists in the inpatient setting.Am J Health Syst Pharm. 2007;64:1071-1079.
28. Lee PY,Han SY,Miyahara RK.Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.Am J Health Syst Pharm. 2013;70:1154-1161.
29. Reilly PA,Lehr T,Haertter S, et al.The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial.J Am Coll Cardiol. 2014;63:321-328.
30. De Caterina R,Husted S,Wallentin L, et al.New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.J Am Coll Cardiol. 2012;59:1413-1425.